BridgeBio Pharma (FRA:2CL) Change In Prepaid Assets : €-2.3 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Change In Prepaid Assets?

BridgeBio Pharma's Change In Prepaid Assets for the quarter that ended in Mar. 2024 was €-3.1 Mil. It means BridgeBio Pharma's Prepaid Assets declined by €3.1 Mil from Dec. 2023 to Mar. 2024 .

BridgeBio Pharma's Change In Prepaid Assets for the fiscal year that ended in Dec. 2023 was €-2.5 Mil. It means BridgeBio Pharma's Prepaid Assets declined by €2.5 Mil from Dec. 2022 to Dec. 2023 .

BridgeBio Pharma Change In Prepaid Assets Historical Data

The historical data trend for BridgeBio Pharma's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Change In Prepaid Assets Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Prepaid Assets

Get a 7-Day Free Trial

-9.58

-5.80

-3.77

7.24

-2.48

BridgeBio Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Prepaid Assets	Get a 7-Day Free Trial															-3.31	4.25	-1.91	-1.58	-3.08

BridgeBio Pharma Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.3 Mil.

BridgeBio Pharma Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma (FRA:2CL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Change In Prepaid Assets

Comparable Companies

Traded in Other Exchanges

BBIO:USA

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

BridgeBio Pharma (FRA:2CL) Headlines

No Headlines